Summary:Thrombotic microangiopathy (TM), manifesting clinically as thrombotic thrombocytopenic purpura or hemolytic uremic syndrome, is an uncommon complication after bone marrow transplantation (BMT). A retrospective analysis of potential risk factors for TM following allogeneic BMT was performed. Clinical data were analyzed from seven patients diagnosed with severe TM and 409 patients who underwent BMT during the same time period and who survived for at least 100 days afterwards. Six of the seven patients with TM received intensive GVHD prophylaxis consisting of cyclosporine, methotrexate and glucocorticoids, whereas only 66 of the 409 patients without TM received this regimen (P Ͻ 0.001, Fisher's exact test). This regimen was administered to patients older than 40 years, or recipients of a mismatched or unrelated allograft. Univariate analysis also revealed an increased risk of TM associated with the use of an unrelated bone marrow donor (P = 0.02), but no significant association with patient age or gender, diagnosis, amount of prior chemotherapy, transplant conditioning regimen or severity of GVHD. A multivariate exact logistic regression analysis revealed that only the type of GVHD prophylaxis had a significant impact on the risk for TM. The combined use of cyclosporine, methotrexate and glucocorticoids as GVHD prophylaxis may predispose to the development of TM following BMT. Keywords: thrombotic thrombocytopenic purpura; hemolytic uremic syndrome; bone marrow transplantation; graftversus-host disease Thrombotic microangiopathy (TM) is a pathological process characterized by occlusion of the microvasculature by hyaline thrombi resulting in microangiopathic hemolytic anemia, thrombocytopenia and end organ dysfunction. Clinically, TM manifests as hemolytic uremic syndrome (HUS) when the renal vasculature is primarily affected, or as thrombotic thrombocytopenic purpura (TTP) when there is diffuse vascular involvement. The onset of TM has been associated with infection by a variety of bacterial or viral pathogens. 1 There is a well-documented association between infection with E. coli strain O157:H7 and the occurrence of HUS. 2,3 Individuals infected with the human immunodeficiency virus have an increased incidence of TTP. 4 TM also occurs in relation to pregnancy; TTP tends to occur in the ante-partum period while HUS is more frequent post-partum. 1 Administration of chemotherapy, especially mitomycin C, has been associated with the development of HUS. 5 These various etiologies are thought to share the ability to induce injury to the vascular endothelium. Plasma exchange is highly effective therapy for TTP; HUS may also respond to this therapy. 3,6 TM is an uncommon complication of allogeneic bone marrow transplantation (BMT). More than 63 cases of TM have been reported to occur in this setting. 7 The first case of TM following allogeneic BMT was observed during the earliest use of cyclosporine (CsA) prophylaxis for graftversus-host disease (GVHD). 8 Subsequently, the occurrence of TM was found to be signifi...